

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50125/036001

Serial No.

09/980,177

Applicant

Jochmus et al.

Filing Date

November 29, 2001

Group

IDS Filed

July 24, 2002

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. §1.98(b))

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
AJ	WO 93/20844	10/28/93	PCT	—	—	
	WO 93/02184	02/04/93	PCT	—	—	
	WO 94/20137	09/15/94	PCT	—	—	
	WO 94/05792	03/17/94	PCT	—	—	
	WO 96/11272	04/18/96	PCT	—	—	
	WO 91/18294	11/28/91	PCT	—	—	
	WO 92/05248	04/02/92	PCT	—	—	
	WO 92/10513	06/25/92	PCT	—	—	
	WO 93/22338	11/11/93	PCT	—	—	
	WO 95/01374	01/12/95	PCT	—	—	
	WO 96/33737	10/31/96	PCT	—	—	
	WO 98/05790	02/12/98	PCT	—	—	
	WO 98/23752	06/04/98	PCT	—	—	
	WO 99/18220	04/15/99	PCT	—	—	
	WO 99/65522	12/23/99	PCT	—	—	
	WO 99/03885	01/28/99	PCT	—	—	
	2,140,591	07/21/95	Canada	—	—	
	0 375 555	06/27/90	Europe	—	—	
	0 386 734	09/12/90	Europe	—	—	
	0 451 550 A2	10/16/91	Europe	—	—	
	2 279 651	06/28/94	United Kingdom	—	—	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

EXAMINER

AJ ✓

DATE CONSIDERED

7/25/03

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50125/036001

Serial No.

09/980,177

Applicant

Jochmus et al.

Filing Date

November 29, 2001

Group

IDS Filed

July 24, 2002

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

37 C.F.R. §1.98(b))

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
AJ	4,777,239	10/11/88	Schoolnik et al.			
	5,415,995	05/16/95	Schoolnik et al.			
	5,547,846	08/20/96	Bartsch et al.			
	5,662,907	09/02/97	Kubo et al.			
	5,629,161	05/13/97	Müller et al.			
	5,747,269	05/05/98	Rammensee et al.			
	6,025,163	02/15/00	Shamanin et al.			
	6,183,746 B1	02/06/01	Urban et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

AJ	Altman et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes," <i>Science</i> 274:94-96 (1996).
	Baker et al., "Structures of Bovine and Human Papillomaviruses," <i>Biophys. J.</i> 60:1445-1456 (1991).
	De Bruijn et al., "Mechanisms of Induction of Primary Virus-Specific Cytotoxic T Lymphocyte Responses," <i>Eur. J. Immunol.</i> 22:3013-3020 (1992).
	De Bruijn et al., "Peptide Loading of Empty Major Histocompatibility Complex Molecules on RMA-S Cells Allows the Induction of Primary Cytotoxic T Lymphocyte Responses," <i>Eur. J. Immunol.</i> 21:2963-2970 (1991).
	De Gruij et al., "Immune Responses Against Human Papillomavirus (HPV) Type 16 Virus-Like Particles in a Cohort Study of Women with Cervical Intraepithelial Neoplasia 1. Differential T-Helper and IgG Responses in Relation to HPV Infection and Disease Outcome," <i>Journal of General Virology</i> 80:399-408 (1999).
	Dunbar et al., "Direct isolation, Phenotyping and Cloning of Low-Frequency Antigen-Specific Cytotoxic T Lymphocytes From Peripheral Blood," <i>Current Biology</i> 8:413-416 (1998).
	Felkamp et al., "Vaccination with a Cytotoxic T Lymphocyte-Containing Peptide Protects Against a Tumor Induced by Human Papillomavirus Type 16-Transformed Cells," <i>Eur. J. Immunol.</i> 23:2242-2249 (1993).
	Gossen et al., "Inducible Gene Expression Systems for High Eukaryotic Cells," <i>Current Opinion in Biotechnology</i> 5:516-520 (1994).

EXAMINER

AJ

DATE CONSIDERED

7/25/03

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50125/036001

Serial No.

09/980,177

Applicant

Jochmus et al.

Filing Date

November 29, 2001

Group

IDS Filed

July 24, 2002

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. §1.98(b))

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

AS	Heino et al., "Human Papillomavirus Type 16 Capsids Expose Multiple Type-Restricted and Type-Common Antigenic Epitopes," <i>Journal of General Virology</i> 76:1141-1153 (1995).
	Kast et al., "Role of HLA-A Motifs in Identification of Potential CTL Eptiopes in Human Papillomavirus Type 16 E6 and E7 Proteins," <i>Journal of Immunology</i> 152:3904-3912 (1994).
	Krchnak et al., "Synthetic Peptides Derived From E7 Region of Human Papillomavirus Type 16 used as Antigens in ELISA," <i>Journal of General Virology</i> 71:2719-2724 (1990).
	Müller et al., "Identification of Seroreactive Regions of the Human Papillomavirus Type 16 Proteins E4, E6, E7, and L1," <i>Journal of General Virology</i> 71:2709-2717 (1990).
	Müller et al., "Chimeric Papillomavirus-Like Particles," <i>Virology</i> 234:94-111 (1997).
	Nieland et al., "Chimeric Papillomavirus Virus-Like Particles Induce a Murine Self-Antigen-Specific Protective and Therapeutic Antitumor Immune Response," <i>Journal of Cellular Biochemistry</i> 71:145-152 (1999).
	Parker et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <i>Journal of Immunology</i> 152:163-175 (1994).
	Peng et al., "Papillomavirus Virus-Like Particles Can Deliver Defined CTL Epitopes to the MHC Class I Pathway," <i>Virology</i> 240:147-157 (1998).
	Rudolf et al., "Induction of HPV16 Capsid Protein-Specific Human T Cell Responses by Virus-Like Particles," <i>Biol. Chem.</i> 380:335-340 (1999).
	Schäfer et al., "Immune Response to Human Papillomavirus 16 L1E7 Chimeric Virus-Like Particles: Induction of Cytotoxic T Cells and Specific Tumor Protection," <i>Int. J. Cancer</i> 81:881-888 (1999).
	Sijts et al., "Cytotoxic T Lymphocytes Against the Antigen-Processing-Defective RMA-S Tumor Cell Line," <i>Eur. J. Immunol.</i> 22:1639-1642 (1992).
	Sijts et al., "Immunodominant Mink Cell Focus-Inducing Murine Leukemia Virus (MuLV)-Encoded CTL Epitope, Identified by Its MHC Class I-Binding Motif, Explains MuLV-Type Specificity of MCF-Directed Cytotoxic T Lymphocytes," <i>Journal of Immunology</i> 152:106-116 (1994).
	Tsukui et al., "Interleukin 2 Production <i>in Vitro</i> by Peripheral Lymphocytes in Response to Human Papillomavirus-Derived Peptides: Correlation with Cervical Pathology," <i>Cancer Research</i> 56:3967-3974 (1996).
	Zhou et al., "Definition of Linear Antigenic Regions of the HPV 16 L1 Capsid Protein Using Synthetic Virion-Like Particles," <i>Virology</i> 189:592-599 (1992).
↓	Zwicker et al., "Cell-Cycle Regulation of Gene Expression by Transcriptional Repression," <i>TIG</i> 13:3-6 (1997).

EXAMINER

AS

DATE CONSIDERED

7/25/03

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.